vs
Profound Medical Corp.（PROF）与Vivos Therapeutics, Inc.（VVOS）财务数据对比。点击上方公司名可切换其他公司
Profound Medical Corp.的季度营收约是Vivos Therapeutics, Inc.的1.6倍（$6.0M vs $3.8M），Profound Medical Corp.净利率更高（-136.8% vs -180.3%，领先43.5%）
康派集团医疗SE & Co. KGaA是一家总部位于德国科布伦茨的上市软件企业，专注于为医疗领域开发并提供相关软件产品，面向诊所、药房、医学实验室与医院推出支持诊疗及运营工作的云化数字应用软件。截至2022年，该公司全球员工规模超9200人，业务覆盖56个国家，拥有超过160万用户。
Beam Therapeutics是一家总部位于美国马萨诸塞州剑桥市的美国生物技术企业，专注于基因疗法与基因编辑领域的研发工作。公司依托CRISPR碱基编辑和引导编辑技术开发疗法，可在不产生DNA双链断裂的情况下，对DNA序列中的单个核苷酸进行酶修饰。
PROF vs VVOS — 直观对比
营收规模更大
PROF
是对方的1.6倍
$3.8M
净利率更高
PROF
高出43.5%
-180.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $6.0M | $3.8M |
| 净利润 | $-8.2M | $-6.9M |
| 毛利率 | 66.8% | 78.1% |
| 营业利润率 | -123.3% | -166.8% |
| 净利率 | -136.8% | -180.3% |
| 营收同比 | — | 3.4% |
| 净利润同比 | — | -143.8% |
| 每股收益（稀释后） | $0.27 | $-0.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PROFVVOS
| Q4 25 | $6.0M | $3.8M | ||
| Q3 25 | $5.1M | $6.8M | ||
| Q2 25 | $2.0M | $3.8M | ||
| Q1 25 | $2.3M | $3.0M | ||
| Q4 24 | — | $3.7M | ||
| Q3 24 | — | $3.9M | ||
| Q2 24 | — | $4.1M | ||
| Q1 24 | — | $3.4M |
净利润PROFVVOS
| Q4 25 | $-8.2M | $-6.9M | ||
| Q3 25 | $-8.0M | $-5.4M | ||
| Q2 25 | $-15.7M | $-5.0M | ||
| Q1 25 | $-10.7M | $-3.9M | ||
| Q4 24 | — | $-2.8M | ||
| Q3 24 | — | $-2.6M | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | — | $-3.8M |
毛利率PROFVVOS
| Q4 25 | 66.8% | 78.1% | ||
| Q3 25 | 77.7% | 58.0% | ||
| Q2 25 | 81.7% | 55.2% | ||
| Q1 25 | 79.2% | 50.0% | ||
| Q4 24 | — | 56.7% | ||
| Q3 24 | — | 60.5% | ||
| Q2 24 | — | 65.4% | ||
| Q1 24 | — | 56.7% |
营业利润率PROFVVOS
| Q4 25 | -123.3% | -166.8% | ||
| Q3 25 | -176.2% | -69.8% | ||
| Q2 25 | -696.9% | -127.4% | ||
| Q1 25 | -477.0% | -129.9% | ||
| Q4 24 | — | -75.9% | ||
| Q3 24 | — | -68.5% | ||
| Q2 24 | — | -47.8% | ||
| Q1 24 | — | -110.7% |
净利率PROFVVOS
| Q4 25 | -136.8% | -180.3% | ||
| Q3 25 | -157.7% | -79.6% | ||
| Q2 25 | -792.3% | -131.2% | ||
| Q1 25 | -458.1% | -128.1% | ||
| Q4 24 | — | -76.4% | ||
| Q3 24 | — | -67.8% | ||
| Q2 24 | — | -47.6% | ||
| Q1 24 | — | -110.1% |
每股收益（稀释后）PROFVVOS
| Q4 25 | $0.27 | $-0.58 | ||
| Q3 25 | $0.26 | $-0.49 | ||
| Q2 25 | $0.52 | $-0.55 | ||
| Q1 25 | $0.36 | $-0.45 | ||
| Q4 24 | — | $0.41 | ||
| Q3 24 | — | $-0.40 | ||
| Q2 24 | — | $-0.60 | ||
| Q1 24 | — | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $59.7M | $2.0M |
| 总债务越低越好 | $4.5M | $2.9M |
| 股东权益账面价值 | $66.4M | $-1.5M |
| 总资产 | $77.5M | $25.2M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资PROFVVOS
| Q4 25 | $59.7M | $2.0M | ||
| Q3 25 | $24.8M | $3.1M | ||
| Q2 25 | $35.2M | $4.4M | ||
| Q1 25 | $46.4M | $2.3M | ||
| Q4 24 | — | $6.3M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $6.9M | ||
| Q1 24 | — | $2.6M |
总债务PROFVVOS
| Q4 25 | $4.5M | $2.9M | ||
| Q3 25 | $4.5M | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $4.5M | — | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | — | $1.2M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | — |
股东权益PROFVVOS
| Q4 25 | $66.4M | $-1.5M | ||
| Q3 25 | $32.1M | $2.5M | ||
| Q2 25 | $39.3M | $4.6M | ||
| Q1 25 | $50.8M | $4.4M | ||
| Q4 24 | — | $8.0M | ||
| Q3 24 | — | $7.7M | ||
| Q2 24 | — | $6.3M | ||
| Q1 24 | — | $582.0K |
总资产PROFVVOS
| Q4 25 | $77.5M | $25.2M | ||
| Q3 25 | $42.3M | $25.6M | ||
| Q2 25 | $49.7M | $26.0M | ||
| Q1 25 | $60.9M | $11.3M | ||
| Q4 24 | — | $15.3M | ||
| Q3 24 | — | $15.3M | ||
| Q2 24 | — | $15.8M | ||
| Q1 24 | — | $11.8M |
负债/权益比PROFVVOS
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.11× | — | ||
| Q1 25 | 0.09× | — | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.19× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.6M | $-3.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-5.3M |
| 自由现金流率自由现金流/营收 | — | -139.7% |
| 资本支出强度资本支出/营收 | — | 40.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-17.8M |
8季度趋势，按日历期对齐
经营现金流PROFVVOS
| Q4 25 | $-6.6M | $-3.8M | ||
| Q3 25 | $-9.6M | $-4.2M | ||
| Q2 25 | $-13.7M | $-3.5M | ||
| Q1 25 | $-8.3M | $-3.8M | ||
| Q4 24 | — | $-2.9M | ||
| Q3 24 | — | $-4.2M | ||
| Q2 24 | — | $-3.0M | ||
| Q1 24 | — | $-2.5M |
自由现金流PROFVVOS
| Q4 25 | — | $-5.3M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-4.3M | ||
| Q1 25 | — | $-3.9M | ||
| Q4 24 | — | $-3.1M | ||
| Q3 24 | — | $-4.4M | ||
| Q2 24 | — | $-3.1M | ||
| Q1 24 | — | $-2.7M |
自由现金流率PROFVVOS
| Q4 25 | — | -139.7% | ||
| Q3 25 | — | -62.6% | ||
| Q2 25 | — | -111.6% | ||
| Q1 25 | — | -129.9% | ||
| Q4 24 | — | -84.0% | ||
| Q3 24 | — | -113.4% | ||
| Q2 24 | — | -76.7% | ||
| Q1 24 | — | -78.0% |
资本支出强度PROFVVOS
| Q4 25 | — | 40.0% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 20.2% | ||
| Q1 25 | — | 4.0% | ||
| Q4 24 | — | 4.5% | ||
| Q3 24 | — | 5.0% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 4.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PROF
暂无分部数据
VVOS
| Services | $3.2M | 84% |
| Products | $594.0K | 16% |
